ijms-logo

Journal Browser

Journal Browser

Future Perspectives and Challenges: Interleukins in Immune Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 20 January 2025 | Viewed by 776

Special Issue Editor


E-Mail Website
Guest Editor
Department of Immunology, Yamagata University Faculty of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan
Interests: biodefence; cancer immunity; cytokine; diversity of myeloid cell; diversity of cell signaling; immunology; inflammatory disease; innate immunity; myeloid-derived suppressor cell (MDSC); neutrophils
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Through the systematic examination and analysis of the interleukins produced by immune cells, the elucidation of pathogeneses of diseases has been pursued. Currently, it has become possible to limit disease pathogenesis through the control of immune responses in various diseases, and as a strategy for immune control, the suppression of immune cell activation is being carried out through various methods.

On the other hand, new interleukin actions and producing cells have been identified, and novel subsets and plasticity have been elucidated even in known immune cells. Furthermore, issues such as the decrease in therapeutic effects due to neutralizing antibodies have become clearer and need to be addressed.

In this Special Issue, we aim to highlight the problems to be addressed in various diseases, the actions of interleukins that may provide new explanations for their pathogeneses, and the methods and possibilities for new clinical applications, thereby currently marking the starting point of budding and emerging new immunotherapies.

Specifically, we are soliciting original articles and reviews targeting diseases, immune responses, and immunotherapies such as those listed below:

  • Autoimmune disease;
  • Inflammatory disease;
  • Inflammaging (aging, obesity, atherosclerosis, metabolism);
  • Tumor immunity;
  • Sepsis;
  • Cytokine and receptor;Regulatory/suppressor cells;
  • Novel therapy (aptamer, antibody therapeutic, genetically modified cells, cell adsorption).

Dr. Yuji Takeda
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune disease
  • interleukin
  • cytokine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 337 KiB  
Review
Selected Interleukins Relevant to Multiple Sclerosis: New Directions, Potential Targets and Therapeutic Perspectives
by Hubert Mado, Artur Stasiniewicz, Monika Adamczyk-Sowa and Paweł Sowa
Int. J. Mol. Sci. 2024, 25(20), 10931; https://doi.org/10.3390/ijms252010931 - 11 Oct 2024
Viewed by 546
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that progresses with demyelination and neurodegeneration. To date, many studies have revealed the key role of interleukins in the pathogenesis of MS, but their impact has not been fully [...] Read more.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that progresses with demyelination and neurodegeneration. To date, many studies have revealed the key role of interleukins in the pathogenesis of MS, but their impact has not been fully explained. The aim of the present study was to collect and review the results obtained so far regarding the influence of interleukins on the development and course of MS and to assess the potential for their further use. Through the platform “PubMed”, terms related to interleukins and MS were searched. The following interval was set as the time criterion: 2014–2024. A total of 12,731 articles were found, and 100 papers were subsequently used. Cells that produce IL-10 have a neuroprotective effect, whereas those that synthesize IL-6 most likely exacerbate neuroinflammation. IL-12, IL-23 and IL-18 represent pro-inflammatory cytokines. It was found that treatment with an anti-IL-12p40 monoclonal antibody in a study group of MS patients showed a beneficial effect. IL-4 is a pleiotropic cytokine that plays a significant role in type 2 immune responses and inhibits MS progression. IL-13 is an anti-inflammatory cytokine through which the processes of oligodendrogenesis and remyelination occur more efficiently. The group of interleukins discussed in our paper may represent a promising starting point for further research aimed at finding new therapies and prognostic markers for MS. Full article
(This article belongs to the Special Issue Future Perspectives and Challenges: Interleukins in Immune Diseases)
Back to TopTop